Results: 1107
Fixed-dose Combination of Dapagliflozin and Linagliptin in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Randomized Double-blind Multicenter Trial.
- Published in:
- Journal of Diabetology: Official Journal of Diabetes in Asia Study Group, 2025, v. 16, n. 1, p. 50, doi. 10.4103/jod.jod_169_24
- By:
- Publication type:
- Article
Role of Metformin Monotherapy Vs Metformin Plus Dapagliflozin in New Onset T2DM Among 40 Plus Obese Women in Glycaemic Control.
- Published in:
- JK Science, 2024, v. 26, n. 4, p. 209
- By:
- Publication type:
- Article
Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand: SGLT2i for Thai Diabetes with HF Patients: T. Kongmalai et al.
- Published in:
- PharmacoEconomics - Open, 2025, v. 9, n. 1, p. 69, doi. 10.1007/s41669-024-00526-2
- By:
- Publication type:
- Article
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Front Cover: Facile Approach to C‐Glucosides by Using a Protecting‐Group‐Free Hiyama Cross‐Coupling Reaction: High‐Yielding Dapagliflozin Synthesis (Chem. Eur. J. 41/2021).
- Published in:
- Chemistry - A European Journal, 2021, v. 27, n. 41, p. 10484, doi. 10.1002/chem.202101994
- By:
- Publication type:
- Article
Facile Approach to C‐Glucosides by Using a Protecting‐Group‐Free Hiyama Cross‐Coupling Reaction: High‐Yielding Dapagliflozin Synthesis.
- Published in:
- Chemistry - A European Journal, 2021, v. 27, n. 41, p. 10488, doi. 10.1002/chem.202101995
- By:
- Publication type:
- Article
Facile Approach to C‐Glucosides by Using a Protecting‐Group‐Free Hiyama Cross‐Coupling Reaction: High‐Yielding Dapagliflozin Synthesis.
- Published in:
- Chemistry - A European Journal, 2021, v. 27, n. 41, p. 10583, doi. 10.1002/chem.202101052
- By:
- Publication type:
- Article
Dapagliflozin and the initial glomerular filtration rate decline in advanced-stage non-diabetic chronic kidney disease.
- Published in:
- Clinical & Experimental Nephrology, 2022, v. 26, n. 12, p. 1242, doi. 10.1007/s10157-022-02260-7
- By:
- Publication type:
- Article
Peritoneal Glucose Uptake Reduction by Sodium-Glucose Co-Transporter 2 Inhibitors in Clinical Peritoneal Dialysis.
- Published in:
- Blood Purification, 2024, v. 53, n. 9, p. 768, doi. 10.1159/000538978
- By:
- Publication type:
- Article
STUDY OF THE IDENTITY OF THE POLYMORPHIC FORM OF API-DAPAGLIFLOSIN DERIVATIVE AND OF ITS PERMANENCY STRUCTURE UNDER THE INFLUENCE OF THE TABLETING PROCESS.
- Published in:
- ScienceRise: Pharmaceutical Science, 2024, v. 49, n. 3, p. 114, doi. 10.15587/2519-4852.2024.289293
- By:
- Publication type:
- Article
STUDY OF THE IDENTITY OF THE POLYMORPHIC FORM OF API-DAPAGLIFLOSIN DERIVATIVE AND OF ITS PERMANENCY STRUCTURE UNDER THE INFLUENCE OF THE TABLETING PROCESS.
- Published in:
- ScienceRise: Pharmaceutical Science, 2024, v. 49, n. 3, p. 86, doi. 10.15587/2519-4852.2024.289293
- By:
- Publication type:
- Article
SGLT-2 INHIBITORS AS POTENTIAL ANTICONVULSANTS: EMPAGLIFLOZIN, BUT NOT DAPAGLIFLOZIN, RENDERS A PRONOUNCED EFFECT AND POTENTIATES THE SODIUM VALPROATE ACTIVITY IN PENTYLENETETRAZOLE-INDUCED SEIZURES.
- Published in:
- ScienceRise: Pharmaceutical Science, 2022, v. 39, n. 5, p. 83, doi. 10.15587/2519-4852.2022.266065
- By:
- Publication type:
- Article
Recurrent Syncope in a Young Man: What Lies Underneath?
- Published in:
- Indian Journal of Clinical Cardiology, 2024, v. 5, n. 3, p. 278, doi. 10.1177/26324636241249530
- By:
- Publication type:
- Article
New Developments in Cardiology with Implications in Clinical Practice.
- Published in:
- Indian Journal of Clinical Cardiology, 2023, v. 4, n. 1, p. 62, doi. 10.1177/26324636221149466
- By:
- Publication type:
- Article
Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
- Published in:
- Cellular Physiology & Biochemistry (Cell Physiol Biochem Press GmbH & Co. KG), 2019, v. 53, n. 5, p. 865, doi. 10.33594/000000178
- By:
- Publication type:
- Article
Journal Scan.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Effect of the use of dapagliflozin in diuresis, natriuriesis, and in ultrafiltration and peritoneal elimination of sodium in patients with refractory heart failure: DAPA-DP study.
- Published in:
- Renal Replacement Therapy, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s41100-024-00594-4
- By:
- Publication type:
- Article
Letter: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2021, v. 30, n. 1, p. 72, doi. 10.7570/jomes20133
- By:
- Publication type:
- Article
Response: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2021, v. 30, n. 1, p. 74, doi. 10.7570/jomes21006
- By:
- Publication type:
- Article
Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2018, v. 27, n. 1, p. 1, doi. 10.7570/jomes.2018.27.1.1
- By:
- Publication type:
- Article
Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2017, v. 26, n. 2, p. 107, doi. 10.7570/jomes.2017.26.2.107
- By:
- Publication type:
- Article
SGLT2 inhibitors.
- Published in:
- SA Pharmaceutical Journal Incorporating Pharmacy Management, 2018, v. 85, n. 1, p. 72
- By:
- Publication type:
- Article
Effect of sodium-glucose transporter 2 inhibitors on bone.
- Published in:
- Journal of Parathyroid Disease, 2023, v. 11, n. 1, p. 1, doi. 10.34172/jpd.2023.11225
- By:
- Publication type:
- Article
三例达榕列净致糖尿病酮症酸中毒的药学监护及文献分析.
- Published in:
- Pharmaceutial Care & Research, 2021, v. 21, n. 2, p. 133, doi. 10.5428/pcar20210211
- By:
- Publication type:
- Article
Triple Fixed-dose combination of Dapagliflozin, Sitagliptin, and Metformin for People with Type 2 Diabetes in Indian Settings.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2024, v. 14, n. 9, p. 66, doi. 10.22270/jddt.v14i9.6692
- By:
- Publication type:
- Article
The MeViDa Study: Bioequivalence Study of FDC of Dapagliflozin, Vildagliptin SR and Metformin SR in Healthy Indian Volunteers: A Randomized, Open-Label, Crossover Study.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2024, v. 14, n. 7, p. 1, doi. 10.22270/jddt.v14i7.6674
- By:
- Publication type:
- Article
The Effectiveness of SGLT2 Inhibitors in CKD Patients.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2023, v. 13, n. 3, p. 141, doi. 10.22270/jddt.v13i3.5750
- By:
- Publication type:
- Article
Dapagliflozin efficacy as an add-on therapy in double and triple-drug regimens: A meta-analysis of randomized control trial.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2023, v. 13, n. 1, p. 76, doi. 10.22270/jddt.v13i1.5863
- By:
- Publication type:
- Article
Bioequivalence study of a fixed-dose combination of Dapagliflozin/ Vildagliptin Sustained Release tablets in healthy adult male subjects: A Randomized, Open-Label, Crossover Study.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2022, v. 12, n. 6, p. 105, doi. 10.22270/jddt.v12i6.5798
- By:
- Publication type:
- Article
Pharmacophore Modeling Study of Sodium Glucose Co-Transporter-2 (Sglt2) Inhibitor for Antidiabetic Activity.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2020, v. 10, n. 1A, p. 78
- By:
- Publication type:
- Article
In-Vitro Antioxidant Activity and Free Radical Scavenging Potential of Phlorizin Derived Sodium Glucose Cotransporter 2 Inhibitor.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2019, v. 9, n. 4, p. 257, doi. 10.22270/jddt.v9i4.3038
- By:
- Publication type:
- Article
Estimation of Metformin Hydrochloride in Bulk and Formulation by UV - Spectroscopic Area Under Curve Method.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2019, v. 9, n. 3, p. 163, doi. 10.22270/jddt.v9i3.2632
- By:
- Publication type:
- Article
Dapagliflozin in Heart Failure: A Comprehensive Meta-analysis on Functional Capacity, Symptoms, and Safety Outcomes.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 6, p. 753, doi. 10.1007/s40256-024-00669-x
- By:
- Publication type:
- Article
Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 3, p. 455, doi. 10.1007/s40256-024-00648-2
- By:
- Publication type:
- Article
Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
- Published in:
- American Journal of Cardiovascular Drugs, 2024, v. 24, n. 2, p. 313, doi. 10.1007/s40256-024-00632-w
- By:
- Publication type:
- Article
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 6, p. 609, doi. 10.1007/s40256-023-00601-9
- By:
- Publication type:
- Article
Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 3, p. 323, doi. 10.1007/s40256-023-00578-5
- By:
- Publication type:
- Article
Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review.
- Published in:
- American Journal of Cardiovascular Drugs, 2023, v. 23, n. 2, p. 127, doi. 10.1007/s40256-022-00564-3
- By:
- Publication type:
- Article
Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 3, p. 325, doi. 10.1007/s40256-021-00506-5
- By:
- Publication type:
- Article
Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 6, p. 701, doi. 10.1007/s40256-021-00503-8
- By:
- Publication type:
- Article
Effects of Dapagliflozin on Cardiovascular Events, Death, and Safety Outcomes in Patients with Heart Failure: A Meta-Analysis.
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 3, p. 321, doi. 10.1007/s40256-020-00441-x
- By:
- Publication type:
- Article
The effect of anti-diabetic drugs on the musculoskeletal system in women.
- Published in:
- Romanian Journal of Diabetes Nutrition & Metabolic Diseases, 2021, v. 28, n. 2, p. 223, doi. 10.46389/rjd-2021-1034
- By:
- Publication type:
- Article
The Emerging Role of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes. Focus on Dapagliflozin.
- Published in:
- Romanian Journal of Diabetes Nutrition & Metabolic Diseases, 2016, v. 23, n. 1, p. 113, doi. 10.1515/rjdnmd-2016-0014
- By:
- Publication type:
- Article
DELIVER: Extending the benefits of SGLT-2 inhibitors.
- Published in:
- Global Cardiology Science & Practice, 2023, v. 2023, n. 3, p. 1, doi. 10.21542/gcsp.2023.21
- By:
- Publication type:
- Article
Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07250-z
- By:
- Publication type:
- Article
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-03773-z
- By:
- Publication type:
- Article
Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1205834
- By:
- Publication type:
- Article
VALIDATED RP-HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF CANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN AND METFORMIN.
- Published in:
- International Journal of Pharmaceutical, Chemical & Biological Sciences, 2018, v. 8, n. 1, p. 1
- By:
- Publication type:
- Article
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
- Published in:
- Drugs & Aging, 2016, v. 33, n. 7, p. 511, doi. 10.1007/s40266-016-0382-1
- By:
- Publication type:
- Article